Form 8-K - Current report:
SEC Accession No. 0000950170-24-130564
Filing Date
2024-11-25
Accepted
2024-11-25 16:10:07
Documents
13
Period of Report
2024-11-25
Items
Item 2.05: Cost Associated with Exit or Disposal Activities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alec-20241125.htm   iXBRL 8-K 45715
2 EX-99.1 alec-ex99_1.htm EX-99.1 24931
3 GRAPHIC img61176764_0.jpg GRAPHIC 27178
  Complete submission text file 0000950170-24-130564.txt   228669

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT alec-20241125.xsd EX-101.SCH 24837
15 EXTRACTED XBRL INSTANCE DOCUMENT alec-20241125_htm.xml XML 4686
Mailing Address 131 OYSTER POINT BLVD., SUITE 600 SOUTH SAN FRANCISCO CA 94080
Business Address 131 OYSTER POINT BLVD., SUITE 600 SOUTH SAN FRANCISCO CA 94080 415-231-5660
Alector, Inc. (Filer) CIK: 0001653087 (see all company filings)

EIN.: 822933343 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38792 | Film No.: 241495966
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)